Logo image of DNLI

DENALI THERAPEUTICS INC (DNLI) Stock Fundamental Analysis

NASDAQ:DNLI - Nasdaq - US24823R1059 - Common Stock - Currency: USD

16.44  +0.38 (+2.37%)

After market: 16.44 0 (0%)

Fundamental Rating

2

Taking everything into account, DNLI scores 2 out of 10 in our fundamental rating. DNLI was compared to 566 industry peers in the Biotechnology industry. The financial health of DNLI is average, but there are quite some concerns on its profitability. DNLI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

DNLI had negative earnings in the past year.
In the past year DNLI has reported a negative cash flow from operations.
DNLI had negative earnings in 4 of the past 5 years.
DNLI had negative operating cash flow in 4 of the past 5 years.
DNLI Yearly Net Income VS EBIT VS OCF VS FCFDNLI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M -400M

1.2 Ratios

Looking at the Return On Assets, with a value of -30.77%, DNLI is in the better half of the industry, outperforming 65.55% of the companies in the same industry.
The Return On Equity of DNLI (-34.38%) is better than 74.20% of its industry peers.
Industry RankSector Rank
ROA -30.77%
ROE -34.38%
ROIC N/A
ROA(3y)-21.89%
ROA(5y)-16.39%
ROE(3y)-26.58%
ROE(5y)-20.75%
ROIC(3y)N/A
ROIC(5y)N/A
DNLI Yearly ROA, ROE, ROICDNLI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10 -20 -30 -40 -50

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for DNLI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
DNLI Yearly Profit, Operating, Gross MarginsDNLI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

More info and screens

5

2. Health

2.1 Basic Checks

DNLI does not have a ROIC to compare to the WACC, probably because it is not profitable.
DNLI has more shares outstanding than it did 1 year ago.
The number of shares outstanding for DNLI has been increased compared to 5 years ago.
DNLI has a worse debt/assets ratio than last year.
DNLI Yearly Shares OutstandingDNLI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
DNLI Yearly Total Debt VS Total AssetsDNLI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

An Altman-Z score of 7.58 indicates that DNLI is not in any danger for bankruptcy at the moment.
DNLI's Altman-Z score of 7.58 is amongst the best of the industry. DNLI outperforms 84.98% of its industry peers.
DNLI has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
DNLI has a Debt to Equity ratio of 0.00. This is comparable to the rest of the industry: DNLI outperforms 45.23% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.58
ROIC/WACCN/A
WACC10.04%
DNLI Yearly LT Debt VS Equity VS FCFDNLI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

DNLI has a Current Ratio of 8.46. This indicates that DNLI is financially healthy and has no problem in meeting its short term obligations.
DNLI has a Current ratio of 8.46. This is in the better half of the industry: DNLI outperforms 75.27% of its industry peers.
DNLI has a Quick Ratio of 8.46. This indicates that DNLI is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 8.46, DNLI is in the better half of the industry, outperforming 75.44% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.46
Quick Ratio 8.46
DNLI Yearly Current Assets VS Current LiabilitesDNLI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B

More info and screens

3

3. Growth

3.1 Past

DNLI shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -147.22%.
Looking at the last year, DNLI shows a very negative growth in Revenue. The Revenue has decreased by -100.00% in the last year.
EPS 1Y (TTM)-147.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.09%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

DNLI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.83% yearly.
The Revenue is expected to grow by 149.71% on average over the next years. This is a very strong growth
EPS Next Y-8.36%
EPS Next 2Y-1.3%
EPS Next 3Y3.18%
EPS Next 5Y16.83%
Revenue Next Year166.48%
Revenue Next 2Y259.22%
Revenue Next 3Y214.51%
Revenue Next 5Y149.71%

3.3 Evolution

DNLI Yearly Revenue VS EstimatesDNLI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
DNLI Yearly EPS VS EstimatesDNLI Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

DNLI reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DNLI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DNLI Price Earnings VS Forward Price EarningsDNLI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DNLI Per share dataDNLI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.3%
EPS Next 3Y3.18%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DNLI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DENALI THERAPEUTICS INC

NASDAQ:DNLI (5/2/2025, 8:00:01 PM)

After market: 16.44 0 (0%)

16.44

+0.38 (+2.37%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-27 2025-02-27/amc
Earnings (Next)05-05 2025-05-05
Inst Owners91.51%
Inst Owner Change0.01%
Ins Owners4.61%
Ins Owner Change0.64%
Market Cap2.39B
Analysts87.2
Price Target38.54 (134.43%)
Short Float %9.9%
Short Ratio9.08
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.87%
Min EPS beat(2)-0.5%
Max EPS beat(2)18.24%
EPS beat(4)2
Avg EPS beat(4)6.14%
Min EPS beat(4)-8.8%
Max EPS beat(4)18.24%
EPS beat(8)4
Avg EPS beat(8)38.34%
EPS beat(12)6
Avg EPS beat(12)26.96%
EPS beat(16)6
Avg EPS beat(16)9.31%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)0
Avg Revenue beat(4)-100%
Min Revenue beat(4)-100%
Max Revenue beat(4)-100%
Revenue beat(8)2
Avg Revenue beat(8)184.22%
Revenue beat(12)4
Avg Revenue beat(12)121.08%
Revenue beat(16)4
Avg Revenue beat(16)75.15%
PT rev (1m)-4.17%
PT rev (3m)-11.65%
EPS NQ rev (1m)0%
EPS NQ rev (3m)13.04%
EPS NY rev (1m)-0.4%
EPS NY rev (3m)3.31%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-77.33%
Revenue NY rev (1m)-10.19%
Revenue NY rev (3m)-46.33%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.94
P/tB 1.94
EV/EBITDA N/A
EPS(TTM)-2.67
EYN/A
EPS(NY)-2.89
Fwd EYN/A
FCF(TTM)-2.5
FCFYN/A
OCF(TTM)-2.39
OCFYN/A
SpS0
BVpS8.47
TBVpS8.47
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -30.77%
ROE -34.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-21.89%
ROA(5y)-16.39%
ROE(3y)-26.58%
ROE(5y)-20.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score1
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 176.96%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.46
Quick Ratio 8.46
Altman-Z 7.58
F-Score1
WACC10.04%
ROIC/WACCN/A
Cap/Depr(3y)141.82%
Cap/Depr(5y)112.16%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-147.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%22.09%
EPS Next Y-8.36%
EPS Next 2Y-1.3%
EPS Next 3Y3.18%
EPS Next 5Y16.83%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year166.48%
Revenue Next 2Y259.22%
Revenue Next 3Y214.51%
Revenue Next 5Y149.71%
EBIT growth 1Y-155.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year1.56%
EBIT Next 3Y3.52%
EBIT Next 5Y18.37%
FCF growth 1Y1.97%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.88%
OCF growth 3YN/A
OCF growth 5YN/A